Compare Cytokinetics Inc (CYTK) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs BlackRock TCP Capital Corp — how do they compare? Cytokinetics Inc trades at $76.83 (market cap $10.63B), while BlackRock TCP Capital Corp trades at $3.92 (market cap $327.64M). The key difference: Cytokinetics Inc is far larger — about 32.4× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TCPC | |
|---|---|---|
Market Cap | $10.63B | $327.64M |
Sector | Technology | Financials |
52-Week High | $87.26 | $7.26 |
52-Week Low | $34.31 | $3.13 |
Enterprise Value | $10.74B | — |
Dividend Yield | — | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
TCPC trades at $3.88, down 1.52% today, with a bullish technical trend and neutral oscillators. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company announced a $523 million portfolio sale to reduce leverage. The stock shows a high P/S ratio of 70.7 but trades below book value with a P/B of 0.59. Dividends of $0.17 per share are scheduled for H1 and H2 2026.
Outlook is mixed: strategic moves and dividend yield near 8.8% offer value, but negative revenue, net losses, and a class action lawsuit pose risks. Analyst consensus leans hold, with 30.8% buy ratings. Further upside depends on successful execution of the strategic review and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
